velscope presentation (short)

3

DETECT THE EARLIEST CHANGES

7Image courtesy of the British Columbia Oral Cancer Prevention Program

Patient DPatient D

Abnormal Tissue?

8Images courtesy of the British Columbia Oral Cancer Prevention Program

Patient DPatient D

Clinical Appearance

Irregular, Dark Area

Biopsy confirmed Carcinoma in situ

9Image courtesy of the British Columbia Oral Cancer Prevention Program

Patient EPatient E

Where Is The Abnormal Tissue?

Polyp

10

Mild dysplasia

CIS

Clinical Appearance

Suspicious region is now clearly visible. Confirmed CIS.

Polyp

Images courtesy of the British Columbia Oral Cancer Prevention Program

Patient EPatient E (continued)(continued)

Polyp(white)

11

Oral Lesions May Show as

Irregular, Dark Areas

Images courtesy of the British Columbia Oral Cancer Prevention Program

Observe or Refer?

Severe Dysplasia

12

An Oral Lesion that Shows No Change in Autofluorescence

Appearing Pale Green

Images courtesy of the British Columbia Oral Cancer Prevention Program

Hyperplasia

Observe or Refer?

14

Pre-clinical discovery

Left palate : low-grade mucoepidermoid carcinoma

15

EXTENSIVE CLINICAL SUPPORT

10+ Years of Research in the Oral Cavity

• 2009 General Dentistry – K. Huff, et al• 2007 Head & Neck – P.M. Williams, et al.• 2006 Clinical Cancer Research – C.F. Poh, et al• 2005 Oral Oncology – deVeld, et al.

Proven Efficacywww.VELscope.com/research

16

Reimbursement Code (US)

D0431

Adjunctive Mucosal ScreeningAdjunctive Mucosal ScreeningAn adjunctive pre-diagnostic test

that aids in detection of mucosal abnormalities including

pre-malignant and malignant lesions.Not to include cytology or biopsy.

Note: This reimbursement code is only valid in the U.S. and it will be different for other countries.